TriVascular revenues jump in Q2

Santa Rosa medical device maker TriVascular Technologies reported its revenues increased 62 percent in the second quarter.|
ROBERT DIGITALE
THE PRESS DEMOCRAT

Santa Rosa medical device maker TriVascular Technologies reported its revenues increased 62 percent in the second quarter.

Sales grew to $7.8 million, up from $4.8 million a year earlier, the company said Wednesday.

“We had a strong second quarter reflecting ongoing momentum in commercializing our innovative Ovation Stent Graft platform,” President and CEO Chris Chavez said in a statement.

The stent graft system repairs abdominal aortic aneurysms, bulges in the aorta that can rupture, causing internal bleeding and death.

TriVascular reported a net loss for the second quarter of $14.6 million, compared to a loss of $12.8 million for a year earlier. That amounted to a loss of 87 cents per share, compared to a loss of $22.33 a year ago before TriVascular’s initial public offering last April.

The company noted that 4,300 patients worldwide have received the Ovation implants.

Robert Digitales

UPDATED: Please read and follow our commenting policy:
  • This is a family newspaper, please use a kind and respectful tone.
  • No profanity, hate speech or personal attacks. No off-topic remarks.
  • No disinformation about current events.
  • We will remove any comments — or commenters — that do not follow this commenting policy.
Send a letter to the editor